Gene · 3274
HRH2: histamine receptor H2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. HRH2: histamine receptor H2. Genes, record 3274. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/3274
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P25021 | Histamine H2 receptor | 359 | 6 | Ensembl, GeneID, HGNC |
Source UniProt
Patents38
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 49118 | P25021 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 576 | P25021 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 34 | P25021 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 1983 | P25021 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 1983 | P25021 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 576 | P25021 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 29664 | P25021 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 34 | P25021 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 29664 | P25021 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 29664 | P25021 | Espacenet |
1 to 10 of 38
See all 38 patentsDrugs15
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BETAZOLE | CHEMBL1201323 | Histamine H2 receptor agonist | AGONIST | ChEMBL |
| BETAZOLE HYDROCHLORIDE | CHEMBL1200949 | Histamine H2 receptor agonist | AGONIST | ChEMBL |
| CIMETIDINE | CHEMBL30 | Histamine H2 receptor antagonist | ANTAGONIST | ChEMBL |
| CIMETIDINE HYDROCHLORIDE | CHEMBL1201051 | Histamine H2 receptor antagonist | ANTAGONIST | ChEMBL |
| EBROTIDINE | CHEMBL1742471 | Histamine H2 receptor antagonist | ANTAGONIST | ChEMBL |
| FAMOTIDINE | CHEMBL902 | Histamine H2 receptor antagonist | ANTAGONIST | ChEMBL |
| LAFUTIDINE | CHEMBL1742461 | Histamine H2 receptor antagonist | ANTAGONIST | ChEMBL |
| METHANTHELINE | CHEMBL1201264 | Histamine H2 receptor antagonist | ANTAGONIST | ChEMBL |
| METHANTHELINE BROMIDE | CHEMBL1200988 | Histamine H2 receptor antagonist | ANTAGONIST | ChEMBL |
| NIZATIDINE | CHEMBL3183075 | Histamine H2 receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 15
See all 15 drugsTrials52
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT06313307 | FAMOTIDINE | ClinicalTrials.gov | ||
| NCT06241183 | FAMOTIDINE | PHASE4 | ClinicalTrials.gov | |
| NCT06207305 | FAMOTIDINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT05946551 | FAMOTIDINE | PHASE3 | 2025-07-17 | ClinicalTrials.gov |
| NCT05163756 | FAMOTIDINE | PHASE3 | ClinicalTrials.gov | |
| NCT05122208 | FAMOTIDINE | ClinicalTrials.gov | ||
| NCT05085574 | FAMOTIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT05084521 | FAMOTIDINE | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT05077332 | FAMOTIDINE | PHASE2 | ClinicalTrials.gov | |
| NCT05043350 | FAMOTIDINE | PHASE2/PHASE3 | ClinicalTrials.gov |
1 to 10 of 52
See all 52 trialsNIH grants730
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | HRH2 papers | Newest fiscal year |
|---|---|---|---|
| ZIADK053200 | Diagnosis, Natural History, Management, tumor biology of Gastrinomas/PETs/Neuroendocrine tumors | 9 | 2025 |
| P30DK056338 | Texas Medical Center Digestive Diseases Center | 8 | 2025 |
| P30DK078392 | Digestive Health Center (DHC): Bench to Bedside Research in Pediatric Digestive Disease | 3 | 2025 |
| T32DK007664 | Research Training in Pediatrics Gastroenterolgy | 3 | 2025 |
| KL2TR002317 | Institutional Career Development Core | 2 | 2025 |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 2 | 2025 |
| R01GM132672 | The ion channel TRPA1 is required for suppression of inflammation | 2 | 2025 |
| R25MH077823 | Research Education for Future Physician-Scientists in Child Psychiatry | 2 | 2025 |
| R35GM118182 | Molecular basis of bioelectronic medicine | 2 | 2025 |
| R35GM124871 | Olfactory receptor-based sensors for biomedical applications | 2 | 2025 |
1 to 10 of 730Source NIH's project files
See all 730 nih grantsPapers2,217
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Cross-Talk Between Histamine H2 Receptor and Glucocorticoid Receptor: Potential Implications in Acute Myeloid Leukemia Treatment. | Pharmacol Res Perspect | 2026 | 42736631 | PubTator, text mining | PubMed |
| Elevated Histamine Receptor 2 and Toll-Like Receptor 7 Expression in Rheumatoid Arthritis: Insights Into Inflammatory Mechanisms and Potential Therapeutic Strategies. | Int J Rheum Dis | 2026 | 42578414 | PubTator, text mining | PubMed |
| Dissociation and tautomerism of some amino-, nitro-, and aminonitrofluoresceins in DMSO: Either resolution or inversion of the Ka1 and Ka2 values. | Spectrochim Acta A Mol Biomol Spectrosc | 2026 | 42526097 | PubTator, text mining | PubMed |
| Myeloid Cell-Derived Thrombospondin-1 Mediates Anti-Metastatic Effects of Histamine Dihydrochloride in B16 Melanoma. | Immunotargets Ther | 2026 | 42281617 | PubTator, text mining | PubMed |
| Investigating the Impact of Bisphenol A on Gastric Cancer Through Network Toxicology and Molecular Docking. | Int J Toxicol | 2026 | 42134865 | PubTator, text mining | PubMed |
| Quantitative deciphering of mammalian histamine receptors through mathematical genomics. | Biochem Biophys Res Commun | 2026 | 41946080 | PubTator, text mining | PubMed |
| Cytotoxic effect of famotidine in breast adenocarcinoma cells line. | North Clin Istanb | 2026 | 41940059 | PubTator, text mining | PubMed |
| Neurotransmitter Systems in Alzheimer's Disease. | Curr Issues Mol Biol | 2026 | 41899485 | PubTator, text mining | PubMed |
| Molecular Markers Distinguishing Early-Stage Mycosis Fungoides From Atopic Dermatitis Skin Lesions. | Exp Dermatol | 2026 | 41888970 | PubTator, text mining | PubMed |
| Harnessing metabolomics and proteomics in a clinical trial for pulmonary arterial hypertension: insights from post-hoc analysis of the REHAB-PH trial. | EBioMedicine | 2026 | 41849831 | PubTator, text mining | PubMed |
1 to 10 of 2,217
See all 2,217 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/3274
GET https://conductscience.org/api/genes/v1/3274/patents?page=2